AMINOCARNITINES

Abstract: Acylated aminocarnitines have utility as competitive inhibitors of carnitine acyl transferases and the unacylated compounds have utility as intermediates for making the acylated compounds.

Description: Description A INOCARNITINES Technical Field The invention is directed to novel carnitine analogues which in competition with acyl carnitines bind and inhibit carnitine acyltransferases. Background Art Carnitine acetyltransferase is found in mammals but its in vivo role has not been definitively established. There is conjecture, however, that it allows acetyl carnitine to buffer the pool of acetyl-Coenzyme A and/or that it may be involved in intracellular trans¬ port of acetyl and other short chain acyl groups. Compounds which competitively bind to and thus inhibit carnitine acetyltransferase, are useful to investigate the in vivo role of carnitine acetyltransferase and to verify or disprove the conjecture. Fritz, I.B. and Schultz, S.K., "Carnitine Acetyltransferase II. Inhibition by Carnitine Analo¬ gues and by Sulfhydryl Reagents", J. Biol. Che ., 240 , 2188-2192 (1965) investigate the carnitine acetyltrans¬ ferase inhibiting power of various carnitine analogues and other compounds. They do this by using carnitine acetyltransferase to catalyze the reaction Acetylcarnitine + Coenzyme A * _=_- acetyl-Coenzyme A + carnitine and measuring the velocity of reaction in the presence of the tested compounds and record results in terms of ! values where lower values indicate greater inhibiting power. The inhibitors uncovered by Fritz and Schultz are relatively weak and are subject to metabolism and thus are not suitable for the role investigation previously mentioned. Carnitine pal ito ltransferase (CPT) has a recognized role in mammals in the following chain of reactions. Outside the mitochondria, it catalyzes the reaction Long chain acyl-Coenzyme A + carnitine _____ long chain acyl carnitine + Coenzyme A The long chain acyl carnitine is carried by carnitine transporter from cytoplasm into the mitochondrial matrix. Inside the mitochondria CPT catalyzes the reaction Long chain acyl carnitine + Coenzyme A • _:— ■*• - long chain acyl-Coenzyme A + carnitine Within the mitochondria, the long chain acyl-Coenzyme A is catabolized to carbon dioxide and in the case of diabetics to ketones leading to ketoacidosis. It has been suggested by G. Tutwiler in Carnitine Biosynthesis, Metabolism and. Functions, Academic Press, N.Y. , pp. 171-173 (1980), that inhibiting the fatty acid catabolism may reverse such ketoacidosis. Com¬ pounds which competively bind to and thus inhibit CPT are useful to investigate whether interruption of fatty acid catabolism does reverse ketoacidosis and are use¬ ful in the treatment of diabetes and as a substitute or supplement for insulin. Bromoacetyl-L-carnitine has been shown _in vitro to have a potent effect against T. Brucei , the causitive agent of African txypanosαmiases. See Gilbert, R. . , Klein, R.A., and Johnson, P., "Bromoacetyl-L-Carnitine: Biochemical and Antitrypanosomal Actions Against Trypanoso a Brucei Brucei", Biochem. Pharmacol. 32, No. 22, 3447-3451 (1983). The potential of bro o- acetyl-L-carnitine is limited in vivo because of toxicity due to release of bromine and/or bromoacetate. A more stable analog would eliminate this toxic effect. Disclosure of the Invention Acylated aminocarnitines have been discovered herein which resist metabolizing and are highly stable and strongly bind to corresponding carnitine acyl- transferases and function as excellent competitive inhibitors thereof and thus provide excellent research tools for investigating the role of the transferases in the body, i.e. for evaluating the specificity of carnitine acyltransferases. The acetylated compounds are useful to investigate the role of carnitine acetyl¬ transferase in the bαdy, i.e. to investigate the specificity of carnitine acetyltransferase. The long chain acyl compounds are useful to investigate the role of fatty acid catabolism in diabetes and to control ketogenesis and as a supplement or substitute for insulin to control the complications of diabetes. Haloacylated compounds herein bind in non-reversible fashion to the corresponding carnitine acyltrans- ferases and thus are longer lasting than the unsub- stituted acyl compounds. Moreover, the haloacylated compounds are stable and thus cure the deficiencies of the bromoac lated carnitines in respect to in vivo treatment of trypanosomiases. Nonacylated aminocarnitines herein are intermediates for the acylated compounds and have the potential for bind¬ ing fatty acids in mammals so that they are excreted. Compounds herein are generally characterized as aminocarnitines and have the structural formula COOH i CH,, CHNHY I wherein Y is selected from the group consisting of -H, -H-S wherein Z is a non-toxic counterion, O - -CR wherein R is selected from the group consisting of -H and aliphatic containing from 1 to 19 carbon atoms, -CCHX'R 1 wherein X 1 is selected from the * group consisting of chlorine, bromine and iodine and R 1 is selected from the group consisting of -H and aliphatic containing from 1 to 18 carbon atoms and wherein X is a non-toxic counterion. Additional compounds herein are the non-toxic esters and salts of the acids described in the above paragraph. Additional compounds herein are the zwitterionic compounds produced by removing H from the -COOH group whereby the -COO serves as the counterion X~ or Z ~ . The compounds herein include hydrates and in such X is provided by OH in the water of hydration. Preferred compounds herein include 3-acetamido-4- trimethylaminobutyric acid-H 2 0 (which may be referred to as acetyl amino carnitine and is hereinafter sometimes referred to as AAC) and 3-amino-4-trimethylaminobutyric acid-HCl ^ (which may be referred to as amino carnitine and is hereinafter sometimes referred to as AC) . Usually the D,L form is synthesized herein. If more potency is desired for a given weight, the L-isomer can be isolated by resolution, e.g. using alkaloid salts. Best Mode for Carrying Out the Invention We turn now in more detail to the description of the amino carnitines herein. Turning* firstly to the acylated and haloacylated amino compounds herein, R and R' are selected so that the acyl chain length ranges up to 20 carbon atoms and can be saturated or unsaturated including, for example, one, two, three or even four double bonds. The acyl chains and the acyl portion of the haloacylated compounds * include, for example ? acetyl, propionyl, butyroyl, caproyl, capryloyl, decanoyl, tridecano ' yl, lauroyl, myristoyl, myristoleoyl, palmitoyl, stearoyl, oleoyl, linoleoyl, linolenoyl, eleostearoyl, arachidoyl, gadoleoyl, and arachidonoyl. Turning now to the counterions X and Z in the description of the above set forth structure, these are uncritical as long as they are non-toxic since they become separated in solution or in a mammal and can be, for example, hydroxide (such as in water of hydration) , chloride, acetate, propionate, phosphate, sulfate, methosulfate, ethosulfate, bicar¬ bonate and carbonate. As indicated above the compounds herein can be in the zwitterionic form wherein hydrogen is removed from the acid group and the resulting COO serves as a counterion in place of X ~ or Z . Turning now to the embodiment which is in the ester or salt form instead of the acid form, theparticular ester group or salt cation is uncritical as long as it is non- oxic since these break down to the acid form in solution or in the body. Thus methyl or ethyl or sodium, for example, are readily substituted for hydrogen in the COOH group. The acyl and haloacyl amino derivatives are coveniently prepared by starting with the free amino compound and acylating with acid chloride or acid anhydride for the acyl compounds and with haloacyl anhydride for the haloacyl compounds (e.g. bromoacetic anhydride for bromoacyl compounds) . Acetyl amino compound is also readily prepared by reacting 6-(chloro ethyl)uracil with dimethylamine, reducing to the dihydrouracil, hydrolyzing to open the ring, acetylating, and then methylating to form the trimethylammonium salt. An alternative route to acetyl amino compound involves reducing. uracil-4-acetic acid using hydrogen and rhodium on alumina, hydrolyzing with water and HC1 to open the ring, acylating and cyclizing with acetic anhydride, opening the ring with ammonia, decarboxylating in a Hoffman reaction with NaOBr, and then methylating with CH.-I to form the quaternary ammonium salt. A second alternative route involves starting with D- or L- aspartic acid, esterifying the 3-carboxyl group with benzyl alcohol, protecting the amino group, e.g. with benzyloxycarbonyl, tert-butyloxycarbonyl or acetyl groups, forming the - dimethylamide using dicyclohexylcarboimide and dimethyl¬ amine, selectively reducing at the 1-position of the carbon chain with tetrabutyl ammonium borohydride, and methylating using CH-I to form the"quaternary ammonium salt: This procedure yields the L- or D-c-minoca itine isorrer directly. Free amino compound is readily formed by hydrolyzing the acetyl amino compound. Alternatively, it is prepared by starting with ethyl 4-bromocrotonate, reacting with trimethylamine to form the quaternary ammonium salt, reacting with ammonia to form amine (NH«) and hydrolyzing to remove ethyl and form the acid. In the description of the above set forth structural formula the free amino compound is des- cribed both where Y is -H and where Y is -E +- Z—. The following specific examples are illustrative of the invention. In the examples, temperatures are in the °C. EXAMPLE I D,L-3-acetamido-4-trimethylaminobutyric acid'H-O, i.e. AAC, was prepared as follows: Dimethylamine (170 ml. of a 40% solution in water, 1.5 moles) and 330 ml of water were mixed by magnetic stirring in a 1 liter Erlenmeyer flask. .6-(chloro- methyl)uracil (80.3 -gm, 0.5 moles) was added to that mixture in portions over a 15 min. period; the reaction was slightly exothermic. The mixture was stirred until it became clear and then for an additional 30 min. The solution was then heated in a boiling water bath and filtered through a steam-heated filter to remove a small amount of insoluble impurities. The clear filtrate was rotary evaporated at reduced pressure to yield a white solid. Water (200 ml) was twice added to the solid and evaporated .to completely remove unreacted dimethylamine. The solid was then suspended in 6 M HC1 (500 ml) and the mixture was swirled in a boiling water bath until a clear solution resulted. That solution was rotary evaporated at reduced pressure to a dry solid and water was added and removed twice as described above. The solid was then dissolved in the minimum volume of hot water and allowed to crystallize as the solution cooled. The crystals were collected by filtration, washed with cold 50% aqueous ethanol and then ether, and dried in a vacuum desiccator over B-O- . The product, 6- (dimethylaminomethyl)uracil-HCl, was obtained as a white solid; mp 282°C; C 7 H.. 2 C1 .,0 2 requires C: 40.88%, H: 5.88%; N: 20.43%; found C: 40.88 , H: 5.66 , N: 20.19 ) • 6- (dimethylaminomethyl) uracil-HCl (10.3 gm, 0.05 moles) and 250 ml of 10% acetic acid in water were placed in a 500 ml Parr bottle. The bottle was flushed briefly with 2 and then 0.5 gm of 5% rhodium on alumina catalyst powder was added. The bottle was attached to a Parr shaking hydrogenator and, after flushing twice with H 2 , was pressurized to 40 PSI with H„ _ Hydrogenation was carried out with shaking at room temperature for 24 hours by which time approximately 0.05 mole of H 2 had been absorbed. The bottle was then flushed with N_ , removed from the hydrogenator and the solution filtered under N- through a bed of Celite. The filtrate was rotary evaporated under reduced pressure to a white solid which was recrystal- lized from 50 ml of hot ethanol to which a few ml of water had been added to achieve nearly complete solubility. The crystals were collected by filtra¬ tion, washed with 5% aqueous ethanol and then ether, and dried in a vacuum desiccator over P-O. . The product, 6-(dimethylaminomethyl) dihydrouracil-HCl, was obtained as a white solid (yield: 9.3 gm, 90%) ; mp: 257-258°C; C 7 H 14 C1N 3 0 2 requires C: 40.49%; H: 6.80%; N: 20.24%; found C: 40.67%; H: 6.79%; N: 19.95%) . 6- (dimethylaminomethyl)dihydrouracil-HCl (10.4 gm, 0.05 moles) was dissolved in 300 ml of 6 N HCl .in a 500 ml round bottom flask. A condenser was fitted and the solution was refluxed for 30 hours using a heating mantle. The solution was then cooled and rotary evaporated to dryness at reduced pressure to yield a white solid. That material was dissolved in 10 ml of water and the resulting solution was applied to the top of a column (2.5 x 45 cm) of Dowex 50 x 8 (H form, 200-400 mesh) . The column was developed using a linear gradient formed between 1 N HCl and 6 N HCl (total volume 1600 ml) ; the gradient was followed with 200 ml of 6 N HCl. Fractions of approxi¬ mately 25 ml were collected; a 10 μl portion of every other fraction was assayed with o-phthalaldehyde to determine where compounds with primary amino groups eluted. 3-amino-4-dimethylaminobutyric acid-HCl- eluted at about 4.5 HCl and was the major o-phthalaldehyde- positive species detected. The appropriate fractions were pooled and rotary evaporated to dryness at reduced pressure. Water was added and removed twice to ensure that no free HCl remained in the product. The resulting white solid, 3-amino-4-dimethylamino- butyric acid-HCl 2 , was pure without recrystalliza- tion (yield 9.2 gm, 84% ); mp 220-221°; C 6 H 16 C1 2 N 2°2- requires C: 32.89%; H: 7.36%; N: 12.79%; found C: 33.04%; H: 7.40%; N: 12.56%). 3-amino-4-dimethylaminobutyric acid-HC1 2 (10.96 gm, 0.05 moles) was dissolved in -300 ml of 0.5 N NaOH (the pH was 10-11) in. a 500 ml Erlenmeyer flask. The solution was chilled to <5° and sodium carbonate (12.4 gm, 0.1 mole) was added. With vigorous magnetic stirring, acetic anhydride (14.8 ml; 150 mmole) was added dropwise over a 15 minute period. After stirring an additional 30 minutes at 0-5°, an aliquot was assayed with o-phthalaldehyde to confirm that no free primary amino groups remained. The mixture was then cautiously acidified to pH 2 with concentrated HCl (C0 2 evolution observed) and the resulting solution was rotary evaporated at reduced pressure to a gummy solid. That material was suspended in 100 ml of concentrated HCl and that mixture was filtered to remove NaCl. The filtrate was rotary evaporated under reduced pressure to yield a white amorphous solid which was not generally further purified. For purposes of characterization, the crude product was chromatographed on Dowex 50 (H ) using the procedure described for 3-amino-4-dimethylaminobutyric acid-HCl 2 . The acetylated product, located by monitoring 2 , Q , eluted at about 2.5 M HCl. Appropriate fractions were pooled, and rotary evaporated at reduced pressure to yield a product contaminated with NaCl. The crude material was dissolved in 25 ml of water and that solution was applied to a column (2.5 x 20 cm) of Dowex 50 x 8 (H , 200-400 mesh) . The column was washed with 1000 ml of water and the product was then eluted with 3 N NH.OH. Fractions containing product were washed with H 2 0 and rotary evaporated to dryness under reduced pressure to yield a white solid. The resulting solid, 3-acetamido-4-dimethylaminobutyric acid-H 2 0, was pure without recrystallization (yield: 8.54 gm, 83% ) ; mp 107-110° ; c g H 16 N 2 0 3" H 2° rec ϊ uires C: 46.59%; H: 8.80%; N: 13.58%; found C: 46.96%; H: 8.86%; N: 13.85%) . 3-acetamido-4-dimethylaminobutyric acid-H„0 (11.2 gm of unpurified material, 0.05 moles) was dissolved in 75 ml of water in a large screw cap bottle and the resulting solution was adjusted to pH 7 with 10 N NaOH. Sodium carbonate (12.4 gm, 0.1 moles), methanol (75 mis) and iodomethane (6.2 mis, 0.1 mole) were then added and the bottle was capped and stirred magnetically at 25° for 24 hours. The solution was then diluted with 250 ml of water and acidified to pH 2 with concentrated HCl. The resulting solution was rotary evaporated under reduced pressure to yield a gummy yellow solid which was suspended in 50 ml of concentrated HCl. That solution was filtered to remove NaCl, and the filtrate was rotary evaporated under reduced pressure to yield a yellow gum. The residue was dissolved in + 20 ml of water and chromatographed on Dowex 50 (H ) as described for 3-amino-4-dimethylaminobutyric acid-HCl-. The product, 3-acetamido-4-trimethyl- aminobutyric acid-H 2 0, located by monitoring the A 2i n °^ t ιe fractions, was eluted at about 3 N HCl. The appropriate fractions were pooled and rotary evaporated ' , at -reduced pressure to yield a white solid contaminated with a small amount of NaCl. That material was dissolved in water and absorbed to a column (2.5 x 20 cm) of Dowex 50 (H ) . After washing with 1000 ml of water, the product was eluted with 750 ml of 3N NH.OH and the appropriate fractions were rotary evaporated to dryness under reduced pressure. The resulting white solid, D,L-3-acetamido-4- trimethyla inobutyric acid-H 2 0, was pure without recrystallization (yield 9.7 gm) ; mp 202-202.5°, C 9 H 18 N 2°3" H 2° rec 3 uires C: 49.07% ; H: 9.15%; N: 12.72%; found C: 49.01%; H: 8.94%; N: 12.53%). EXAMPLE II D,L-3-acetamido-4-trimethylaminobutyric acid'H 2 0, referred to hereinafter as AAC, was for inhibition of carnitine acetyltransferase. The procedure used is described in Fritz, I.B., Schultz, ,S.K. , and Srere, P.A., "Properties of Partially Purified Carnitine Acetyltransferase", J. Biol. Chem., 238, 2509-2517 (1963). The assay was based on the following reactions wherein CAT is used to denote carnitine acetyltrans¬ ferase, CS is used to denote citrate synthase, MDH is used to denote malate dehydrogenase , NAD is used to denote (3-nicotinamide adenine dinucleotide (unreduced form) and NADH is used to denote _ -nicotinamide adenine dinucleotide (reduced form) : Catalyst Reaction (1) CAT Acetylcarnitine + Coenzyme A^= carnitine + acetyl-Coenzyme A (2) CS Acetyl-Coenzyme A +- oxaloacetate citrate + Coenzyme A (3) MDH Malate -f* NAD-?=^oxaloacetate + NADH + .H + The assay is based on the fact that the velocity o reaction to produce acetyl-Coenzyme A is reduced to the extent that CAT is inhibited. Reactions (2) and (3) are a detection system for acetyl-Coenzyme A wherein acetyl-Coenzyme A, as it is produced, reacts with oxaloacetate thereby causing the MDH to catalyze production of oxaloacetate to replace that which is used and resulting in production of NADH which is detected using a spectrophotometer based on its property of absorbing light at 340 mμ. Thus, when CAT is bound and inhibited, therate of NADH production is decreased and the rate of increase of absorbency at 340 mμ is decreased. The results are readily compiled in a Lineweaver-Burk plot of the reciprocal of reaction velocity versus the reciprocal of concentration of of acetylcarnitine and the data can be analyzed to provide K! values as mentioned above. Sixteen runs were carried out. They consisted of a set of 4 runs where 1 mM of D,L-acetylcarnitine (pH 8.0) was included, a set of 4 runs where 2 mM of D,L-acetylcarnitine was included, a set of 4 runs where 5 mM of D,L-acetylcarnitine was included and a set of 4 runs where.10 mM of D,L-acetylcarnitine was included. In each set of runs, one run was conducted without AAC, one run was conducted with 0.1 mM AAC, one run was conducted with 0.5 mM AAC, and one run was conducted with 1.0 mM AAC. Each run was carried out utilizing a cuvette with 1 ml total being added to it. To each cuvette was added 0.7 ml of a premix of aqueous solutions of Tris-HCl buffer, NAD , dithiothreitol, and Tris D,L-malate, pH of 8.0 (concentrations in the premix were as follows: Tris-HCl, 143 mM; NAD , 0.71 mM; dithiothreitol, 4.3 mM; and Tris D,L-malate, 14.3 mM, the selected amount of D,L-acetylcarnitine as described above, 0.05 ml of a 4 mM aqueous solution of Coenzyme A, 0.025 ml of a 168 units/ml solution of CS, 0.025 ml of a 240 units/ml solution of MDH, the selected amount of AAC as described above, and water to 0.995 ml. The D,L-acetylcarnitine was added util¬ izing solution of concentration of 100 mM (in other words 0.010 ml for the first set of runs, 0.020 ml for the second set of runs, 0.050 ml for the third set of runs, 0.100 ml for the fourth set of runs). The AAC was added utilizing solution of concentration of 100 mM (in other words, additions for runs in each set were of 0 ml, 0.001 ml, 0.005 ml and 0.010 ml). After the above described reactants were added, each cuvette and its contents were incubated for 15 minutes at 30°C. Directly after the incubation period, 0.005 ml of CAT (concentration 5 units/ml) was added in each case. The reaction rate in each case was measured as described above as a function of change in absorbance at 340 mμ (providing a time course of NADH formation) and was expressed as μmole NADH/min. (1 mM NADH = 6.2 x Δ 34Q ) . A Lineweaver-Burk plot was then prepared and all the- lines passed through a point on the Y-axis in common with the control (no AAC) proving binding to the same site as acetyl carnitine and proving AAC is a competitive inhibitor of CAT binding it in a 1:1 molar ratio. A KT value for the D,L form of AAC was calcu- 1 -5 -2 -3 lated to be 5 x 10 M which is 10 to 10 times* the K! values found by Fritz and Schultz for the compounds they tested. The AAC was found to inhibit formation of acetyl-Coenzyme A as follows: at a concentration of 0.1 mM, 34%; at a concentration of 0.5 mM, 67%; at a concentration of 1 mM, 81%. The plot indicated that AAC binds to CAT 18 times more tightly than acetylcarnitine. The binding action was found to be reversible by dilution. EXAMPLE III An example of the research utility of AAC is set forth below. Four mice were injected subcutaneously with 0.5 mmol/kg carbon 14 tagged acetylcarnitine. Two of them were injected intra peritoneally with 5 mmol/kg of AAC. The carbon 14 C0 2 output of the mice was monitored every 15 minutes for 6 hours and for each mouse a graph was prepared with time on the X-axis and % of radiolabel C0 2 on the Y-axis. The data indicated a retarded rate of radiolabel C0 2 output for the mice injected with AAC indicating that AAC is active ii vivo in inhibiting CAT and that CAT activity plays a major role in the cata¬ bolism of acetylcarnitine in vivo. The amount of AAC administered was not toxic to the mice. EXAMPLE IV 3-Acetamide-4-trimethylaminobutyric acid-H^O (3.3 gm, 0.15 moles) prepared as set forth in Example I was issolved in 90 mis of 2 N HCl and the resulting solution was refluxed for 6 hours. The solution was then cooled and rotary evaporated at reduced pressure to yield a white solid. That material was dissolved in 20 ml of water and chromatographed on Dowex 50 (H ) as described in Example I. The product (located by assay of fraction aliquots using o-phthalaldehyde) eluted at about 4 N HCl. The appropriate fractions were pooled, and rotary evaporated under reduced pressure to yield a white solid which analysis indicated to be D,L-3-amino-4-trimethylaminobutyric acid-HCl 2 (i.e. AC) (yield 2.7 gm, 77%); mp 214-217°; C_H ιg Cl 2 2 0 2 requires C: 36.06%; H: 7.78%; N: 12.02%; found C: 35.99%; H: 7.79%; N: 11.87%. The AC is readily converted to D,L-3-palmitoamido-4- trimethylaminobutyric acid-H-0 (i.e. PAC) by acylating with palmitoyl chloride. The PAC readily binds to and inhibits carnitine palmitoyltransferase and is useful to investigate the role of fatty acid catabolism in diabetes. Such investigation is readily carried out, e.g. by utilizing mice with drug induced diabetes and intra peritoneally injecting some of these mice with, e.g. 0.1-50 mmol/kg of PAC and observing whether the mice treated with PAC are less ketotic than the other mice. The AC is readily converted to D,L-3-bromoacetamido- 4-trimethylaminobutyric acid-H 2 0 by acylating with bromoacetic anhydride. The formed compound inhibits CAT similarly to AAC but the binding action is irreversible. The term "non-toxic counterion" is used herein in its conventional sense as meaning that the counterion is non-toxic in the amounts that would be present in association with the administration of the compounds in useful amounts. While the foregoing describes preferred embodiments, modifications within the scope of the invention will be evident to those skilled in the art. Thus, the scope of the invention is intended to be defined by the claims.

Claims: CLAIMS 1. Aminocarnitines having the structural formula: wherein Y is selected from the group consisting of - Z— wherei.n Z— i.s a non-toxic counterion, -CR wherein R is selected from the group consisting of -H and aliphatic containing from 1 to 19 carbon Q atoms, -CCHX'R 1 wherein X' is selected from the group consisting of chlorine, bromine and iodine and R" is selected from the group consisting of -H and ali¬ phatic containing from 1 to 18 carbon atoms , and wherein x is a non-toxic counterion; the non-toxic esters and salts thereof; or the zwitterionic form thereof wherein H is emoved from the -COOH group and -COO- serves as the counterion X or Z . 2. as recited in claim 1 wherein Y is -CR wherein R is aliphatic containing from 1 to 19 carbon atoms. 3. Aminocarnitines as recited in claim 2 0 wherein Y is -C-CH-. 4. Aminocarnitine as recited in claim 3 which is 3-acetamido-4-trimethylaminobutyric acid-H 2 0 and X is OH~ and is represented by the H 2 0. 5. Aminocarnitines as recited in claim 1 wherein Y is -H 2 Z . 6. Aminocarnitines as recited in claim 1 wherein X, is chloride. 7. Aminocarnitine as recited in claim 6 which is 3-amino-4-trimethylaminobutyric acid'HCl 2 and X is chloride and is one CI in the HCl- .

Inventors: GRIFFITH OWEN W, JENKINS DEBORAH L, GRIFFITH, OWEN, W., JENKINS, DEBORAH, L.
Applicants: CORNELL RES FOUNDATION INC, CORNELL RESEARCH FOUNDATION, INC.
Application year: 1985
Main classification: C07C101
IPC codes: A61K31, C07C67, C07C227, C07C229, C07C231, C07C233, C12N9, C12P13